Clinical trials: Brain Imaging
Alzheimer's Disease
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy.
- Trial name
- NCT00857415
- Testing
- florbetapir F 18
- Where
- 25 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT01662882
- Testing
- florbetapir (18F)
- Where
- 2 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Autism Spectrum Disorder (ASD)
Brain Stimulation and Sensory Integration in Children With ASD
The goal of this clinical trial is to find out if brain stimulation can help improve sensory integration in children ages 6 to 12 with autism spectrum disorder (ASD).
- Trial name
- NCT07182331
- Testing
- Continuous Theta Burst Stimulation to Bilateral DLPFC
- Where
- 2 sites in Kazakhstan
- Volunteers
- 40 people
- Sponsor
- Neurolab Plus
Fibromyalgia
A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
The purpose of this study is to find out the effect of Lu AG06466 on the body in participants with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental) assessments.
- Trial name
- NCT04974359
- Testing
- Lu AG06466
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Alzheimer's Disease (AD)
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and…
- Trial name
- NCT02681172
- Testing
- Neuraceq (florbetaben 18F), PET
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Solid Tumors, ER/PR Positive Breast Cancer
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
- Conditions
- Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
- Trial name
- NCT01770353
- Testing
- Ferumoxytol, MM-398
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ipsen
Reconstructive Surgical Procedures, Plastic Surgery
Leica Microsystems Sponsored Study to Collect and Confirm Clinical Data on the Performance of the GLOW800 Device When Used in Accordance With Its Intended Use.
This post-market clinical follow-up (PMCF) study aims to confirm the safety and performance of the GLOW800 surgical microscope accessory when used in conjunction with the ARveo8x surgical microscope.
- Conditions
- Reconstructive Surgical Procedures, Plastic Surgery, Vascular Surgical Procedure, Cerebrovascular Disorder
- Trial name
- IMED-GLOW800 (NCT07164040)
- Testing
- The GLOW800, a non-contact, non-invasive device, allows the surgical microscope ARveo 8 and ARveo 8X to produce excitation light and resolve fluorescence emission from the fluorescent agent ICG
- Where
- 3 sites in Portugal, Spain and 1 more
- Volunteers
- 29 people
- Sponsor
- Leica Microsystems (Schweiz) AG
Acute Myocardial Infarction, Restenoses, Coronary
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use…
- Conditions
- Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
- Trial name
- AV-MDR (NCT04573660)
- Testing
- Coronary and peripheral stents, Pacing catheters, Vascular plugs
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 3,784 people
- Sponsor
- Abbott Medical Devices
Normal Human Subjects
Single Photon Emission Computed Tomography of the Normal Human Brain
The objective of the study is to acquire a database of Single Photon Emission Computed Tomographic (SPECT) studies of the brains of normal human subjects in resting and concentrating states.
- Trial name
- NCT01203891
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Amen Clinics, Inc.
Healthy, Alzheimer Disease
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
Up to 20 subjects will receive an injection with [11C]-UCB-J followed by a PET scan on Days 1 and 28
- Trial name
- NCT03577262
- Testing
- [11C]-UCB-J
- Where
- 3 sites in Netherlands
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Healthy Subjects, Depressive Disorder and Anxiety Disorders
Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males
The purpose of this study is to look at how much of a new drug, GSK163090, binds to proteins in the brain and how much stays in the blood over a range of different doses.
- Trial name
- NCT00435695
- Testing
- GSK163090
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Traumatic Brain Injury
Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players
The investigators primary objective is to acquire preliminary data on one-hundred former NFL veterans with at least one full year of professional service using brain SPECT imaging in order to assess the degree to which NFL…
- Trial name
- NCT01515839
- Testing
- Multivitamin Supplement intervention
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Amen Clinics, Inc.
Aneurysm, Brain
Assessing the WAVE Extra Soft Coil in Intracranial Aneurysms and Comparing Imaging Modalities
The objective of this study is to demonstrate the safety and efficacy of the Penumbra SMART COIL® System, including the WAVE™ Extra Soft Coils (WAVE) as a fill and finish coil, in the treatment of intracranial aneurysms.
- Trial name
- SURF (NCT04106583)
- Testing
- WAVE, as part of the SMART COIL System
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 572 people
- Sponsor
- Penumbra Inc.
Alzheimer's Disease
Evaluation of PET Scan Timing Relative to AV-45 Injection Time
This study will re-read 10-minute positron emission tomography (PET) scans acquired in previous clinical studies of AV-45 at 30 and 50 minutes after injection and compare the results.
- Trial name
- NCT01565356
- Testing
- florbetapir F 18
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Non-drug Methods Study in Participants With Alzheimer's Disease
This study will investigate the volume, function and composition of the brain using magnetic resonance imaging (MRI) and positron emission tomography (PET) scanning technology in participants with memory complaints or early signs…
- Trial name
- NCT01459016
- Testing
- PET scan using florbetapir, MRI Scan
- Where
- 16 sites in France
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.
1. To evaluate the diagnostic performance of [18F]-APN-1607 injection PET imaging in detecting uptake patterns consistent with AD neuropathological changes as defined by the National Institute on Aging-Alzheimer's Association…
- Trial name
- NCT07752784
- Testing
- [18F]-APN-1607
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Glioblastoma Multiforme, Brain Neoplasms
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme…
- Conditions
- Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04712721
- Testing
- 68Ga-FF58
- Where
- 2 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS)
[18F]ACI-19626 PET in TDP-43 Proteinopathies
The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic…
- Conditions
- Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS), TDP-43 Proteinopathies, Suspected Limbic Predominant Age-related TDP-43 Encephalopathy (LATE)
- Trial name
- NCT06891716
- Testing
- [18F]ACI-19626
- Where
- Netherlands
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AC Immune SA
Alzheimer Disease, Neurofibrillary Tangle
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's…
- Trial name
- NCT07115238
- Testing
- XTR006
- Where
- China
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group